Kalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Kalaris Therapeutics

11/08/2026 14:32

Kalaris Therapeutics Inc KLRS.OQ reported a quarterly adjusted loss of 48 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -61 cents.  The mean expectation of eight analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -55 cents to -38 cents per share.
Reported revenue was zero​; analysts expected zero. 
Kalaris Therapeutics Inc's reported EPS for the quarter was a loss of 48 cents​.
The company reported a quarterly loss of $11.52 million.
Kalaris Therapeutics Inc shares had fallen by 3.2% this quarter and lost 53.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $18.50, about 78.7% above its last closing price of $3.94
This summary was machine generated from LSEG data August 11 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.49
-0.48
Beat
Mar. 31 2026 
-0.52
-0.46
Beat
Dec. 31 2025 
-0.53
-0.51
Beat
Sep. 30 2025 
-0.65
-0.64
Beat